NCT02755753 - A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis | Biotech Hunter

Enrollment

143

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

April 30, 2016

Conditions

Gastroesophageal Reflux

Interventions

DRUG

Lansoprazole

Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast

DRUG

Rebamipide

Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner

DRUG

Rebamipide-placebo

Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner

Trial Locations (5)

Yang Shiming, Chongqing

Soonchunhyang University Bucheon Hospital, Bucheon-si

Kyungpook National University Medical Center, Daegu

Konyang University Hospital, Daejeon

Severance Hospital, Yonsei University Health System, Seoul